Journal: BMC Cardiovascular Disorders

Article Title: SPAG5 deficiency activates autophagy to reduce atherosclerotic plaque formation in ApoE −/− mice

doi: 10.1186/s12872-024-03945-5

Figure Lengend Snippet: Ox-LDL treatment elevated autophagy and SPAG5 expression in HUVECs. HUVECs were treated with 100 µg/mL ox-LDL for 24 h. HUVECs were cultured in 0.1% DMSO as a control. ( A ) Western blotting examined the expression of SPAG5 in HUVECs. ( B ) ELISA assessed the levels of SPAG5 in the supernatant of HUVECs. ( C ) GFP-LC3 dots were detected. ( D ) Western blotting examined the expression of LC3-I, LC3-II, Beclin-1 and p62 in HUVECs. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. Control

Article Snippet: Primary antibodies for Beclin-1 (Abcam; 1:100), LC3B (Abcam; 1:200) and SPAG5 (Proteintech, 1:500) were incubated on the slides at 4 °C overnight.

Techniques: Expressing, Cell Culture, Control, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: BMC Cardiovascular Disorders

Article Title: SPAG5 deficiency activates autophagy to reduce atherosclerotic plaque formation in ApoE −/− mice

doi: 10.1186/s12872-024-03945-5

Figure Lengend Snippet: SPAG5 knockdown elevated proliferation and reduced apoptosis of ox-LDL-treated HUVECs. HUVECs were transfected with si-SPAG5 or si-NC, followed by 24 h of 100 µg/mL ox-LDL treatment. ( A ) Western blotting examined the expression of SPAG5 in HUVECs. ( B ) CCK-8 assay detected cell proliferation. ( C-D ) Flow cytometry assessed apoptosis. Q1: mechanically-dead cells; Q2 were: late apoptotic cells; Q3: alive cells; Q4: early apoptotic cells. ## P < 0.01, ### P < 0.001 vs. Control. ** P < 0.01, *** P < 0.001 vs. ox-LDL + si-NC.

Article Snippet: Primary antibodies for Beclin-1 (Abcam; 1:100), LC3B (Abcam; 1:200) and SPAG5 (Proteintech, 1:500) were incubated on the slides at 4 °C overnight.

Techniques: Knockdown, Transfection, Western Blot, Expressing, CCK-8 Assay, Flow Cytometry, Control

Journal: BMC Cardiovascular Disorders

Article Title: SPAG5 deficiency activates autophagy to reduce atherosclerotic plaque formation in ApoE −/− mice

doi: 10.1186/s12872-024-03945-5

Figure Lengend Snippet: SPAG5 knockdown activated autophagy and inhibited PI3K/Akt/mTOR signaling pathway. HUVECs were transfected with si-SPAG5 or si-NC, followed by 24 h of 100 µg/mL ox-LDL treatment. ( A-B ) Western blotting examined the expression of PI3K, Akt, p-Akt, mTOR, p-mTOR, LC3-I, LC3-II, Beclin-1, and p62 in HUVECs. ( C ) GFP-LC3 dots were detected. # P < 0.05, ## P < 0.01 vs. Control; * P < 0.05, ** P < 0.01 vs. ox-LDL + si-NC.

Article Snippet: Primary antibodies for Beclin-1 (Abcam; 1:100), LC3B (Abcam; 1:200) and SPAG5 (Proteintech, 1:500) were incubated on the slides at 4 °C overnight.

Techniques: Knockdown, Transfection, Western Blot, Expressing, Control

Journal: BMC Cardiovascular Disorders

Article Title: SPAG5 deficiency activates autophagy to reduce atherosclerotic plaque formation in ApoE −/− mice

doi: 10.1186/s12872-024-03945-5

Figure Lengend Snippet: SPAG5 knockdown elevated proliferation and reduced apoptosis of ox-LDL-treated HUVECs by activating autophagy. HUVECs were transfected with si-SPAG5 or si-NC, followed by 4 h of 1 mM 3-MA treatment. ( A ) CCK-8 assay detected cell proliferation. ( B ) Flow cytometry assessed apoptosis. Q1: mechanically-dead cells; Q2 were: late apoptotic cells; Q3: alive cells; Q4: early apoptotic cells. ( C ) Western blotting examined the expression of LC3-I, LC3-II, Beclin-1 and p62 in HUVECs. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. ox-LDL + si-NC; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. ox-LDL + si-SPAG5.

Article Snippet: Primary antibodies for Beclin-1 (Abcam; 1:100), LC3B (Abcam; 1:200) and SPAG5 (Proteintech, 1:500) were incubated on the slides at 4 °C overnight.

Techniques: Knockdown, Transfection, CCK-8 Assay, Flow Cytometry, Western Blot, Expressing

Journal: BMC Cardiovascular Disorders

Article Title: SPAG5 deficiency activates autophagy to reduce atherosclerotic plaque formation in ApoE −/− mice

doi: 10.1186/s12872-024-03945-5

Figure Lengend Snippet: SPAG5 deficiency alleviated AS development in mice. AS mouse model was established by feeding Western diet, and then injected with LV-sh-SPAG5 or LV-sh-NC. ( A ) The expression of SPAG5 in aorta tissues was detected by immunohistochemistry. ( B, D ) HE staining detected the pathological changes of aortic tissues. ( C ) Oil Red O staining detected the lipid droplets in aorta tissues. ( E ) Western blotting examined the expression of PI3K, Akt, p-Akt, mTOR, and p-mTOR in aortic tissues. ( F ) IHC staining evaluated the expression of LC3 and Beclin-1 in aortic tissues. The black arrows indicate endothelial cells. * P < 0.05, ** P < 0.01 vs. Control; # P < 0.05, ## P < 0.01 vs. AS + sh-NC.

Article Snippet: Primary antibodies for Beclin-1 (Abcam; 1:100), LC3B (Abcam; 1:200) and SPAG5 (Proteintech, 1:500) were incubated on the slides at 4 °C overnight.

Techniques: Western Blot, Injection, Expressing, Immunohistochemistry, Staining, Control

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Summary of tissue expression of Sp17 by type of epithelium or neoplasm

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Expressing, Staining

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Representative Sp17 immunohistochemistry staining in ovarian tissue of serous histology. Examples of Sp17 protein expression in benign and malignant ovarian tissue demonstrating both positive and negative staining and intensity of Sp17 staining are shown. a ) Serous cystadenoma showing tissue staining positive with strong expression of Sp17 in ciliated cells. b ) Serous borderline tumor showing strong Sp17 expression. c ) Grade 1 serous adenocarcinoma negative for Sp17 expression. d ) Grade 1 serous adenocarcinoma showing strong Sp17 expression. e ) Grade 3 serous adenocarcinoma negative for Sp17. f ) Grade 3 serous adenocarcinoma demonstrating strong Sp17 staining. Stroma surrounding epithelial cells is negative

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Immunohistochemistry, Staining, Expressing, Negative Staining

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Univariate and multivariable analysis of Sp17 tissue expression among epithelial ovarian carcinoma specimens

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Expressing, Biomarker Discovery

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Sp17 RNA expression is upregulated in borderline ovarian cancers. Sp17 mRNA expression was analyzed from two publically available patient tumor Oncomine datasets. a Sp17 mRNA levels are significantly increased in borderline ovarian serous adenocarcinoma when compared to ovarian serous adenocarcinoma ( p < 0.001) in Anglesio et al. dataset . b Sp17 mRNA levels are significantly increased in borderline ovarian serous adenocarcinoma when compared to ovarian adenocarcinoma (p < 0.001) in Tothill et al. dataset ( c ) No significant difference in Sp17 expression is seen between grades of ovarian adenocarcinoma ( p = 0.42) . Box encompasses 25th–75th percentile, solid black line indicates median and error bars indicate range. Numbers in parentheses indicate number of cases included in the analysis

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: RNA Expression, Expressing

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Median Sp17 serum concentration by type of ovarian neoplasm

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Concentration Assay

Journal: BMC Cancer

Article Title: Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study

doi: 10.1186/s12885-018-4880-x

Figure Lengend Snippet: Serum Sp17 concentration compared to histology and tissue expression. a Distribution of serum Sp17 concentration in benign ovarian neoplasms, borderline ovarian tumors (BOTs), and epithelial ovarian carcinomas (EOCs). The serum concentration of Sp17 is plotted in standard box and whisker plots on a log 10 scale by histology. No significant difference was found between the serum Sp17 concentration when comparing benign ovarian neoplasms, BOTs, and EOCs. ANOVA test showed that there was a significant difference (p < 0.001) in serum Sp17 concentration among the four main histologic subtypes of EOC: serous, mucinous, endometrioid, and clear cell. Box (interquartile range) encompasses 25th–75th percentile, solid black line indicates median and the whiskers indicate the lowers and highest data values that are still within the 25th and 75th percentile value plus 1.5 times the interquartile range, respectively. The outliers are represented as separate data points. Numbers in parentheses indicate number of cases included in the analysis. b Distribution of serum Sp17 concentration by tissue expression of Sp17. There were 65 patients with both serum and ovarian tissue available, which included benign, borderline, and malignant ovarian neoplasms. The ovarian tissue underwent immunohistochemical (IHC) staining for Sp17 and any expression was considered a positive result. The matching sera for these patients were analyzed for Sp17 concentration using ELISA and the concentration converted to a log 10 scale and represented here in box and whisker plots. There was a significant difference in serum Sp17 levels between IHC positive neoplasms compared to IHC negative neoplasms ( p = 0.027), with IHC positive neoplasms showing higher SP17 levels. Box (interquartile range) encompasses 25th–75th percentile, solid black line indicates median and the whiskers indicate the range. Numbers in parentheses indicate number of cases included in the analysis

Article Snippet: Human sperm surface protein Sp17 ELISA kits (Cusabio Biotech, Wuhan, China) were used to measure the Sp17 serum concentrations.

Techniques: Concentration Assay, Expressing, Whisker Assay, Immunohistochemical staining, Immunohistochemistry, Enzyme-linked Immunosorbent Assay